Skip to main content
31°
Clear
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
League of Women Voters SRI
League of Women Voters WS
Classifieds
Place ad
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Community Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Veracyte Inc
(NQ:
VCYT
)
34.31
+0.57 (+1.69%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Nov 1, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Veracyte Inc
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Raymond James Upgrades Natera & Myriad Genetics, While Downgrading This Stock
January 18, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 18, 2023
January 18, 2023
Via
Benzinga
Expert Ratings for Veracyte
January 05, 2023
Via
Benzinga
Veracyte Earnings Perspective: Return On Capital Employed
November 16, 2022
Via
Benzinga
This Small-Cap Stock Is a No-Brainer Buy
January 18, 2023
This genomic test maker's stock was beaten down in 2022. But it could be heading for a rebound this year.
Via
The Motley Fool
Data Published in JCEM Demonstrate Strong Real-World Performance of Veracyte’s Afirma GSC in Thyroid Cancer Diagnosis
December 15, 2022
From
Veracyte, Inc.
Via
Business Wire
Veracyte Stock Showing Market Leadership; Earns 93 RS Rating
December 01, 2022
Veracyte shows rising price performance, earning an upgrade to its IBD Relative Strength Rating.
Via
Investor's Business Daily
US Stocks Open Lower; Nasdaq Drops 100 Points
November 03, 2022
U.S. stocks traded lower this morning, with the Nasdaq Composite dropping around 100 points on Thursday. The Federal Reserve, on Wednesday, raised interest rates by 75 bps.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023
January 05, 2023
Via
Benzinga
Why Apyx Medical Shares Dipped Over 60%; Here Are 123 Biggest Movers From Yesterday
November 11, 2022
Gainers
Via
Benzinga
Why Greenhill Shares Climbed Around 25%; Here Are 100 Biggest Movers From Yesterday
November 04, 2022
Gainers Huadi International Group Co., Ltd. (NASDAQ: HUDI) shares jumped 242.8% to close at $105.72 on Thursday. The company announced a strategic plan to enter into the clean energy industry.
Via
Benzinga
Why Lincoln National Shares Are Trading Lower By 31%? Here Are 72 Stocks Moving In Thursday's Session
November 03, 2022
Gainers Huadi International Group Co., Ltd. (NASDAQ: HUDI) gained 64% to $50.60.
Via
Benzinga
Veracyte Announces Third Quarter 2022 Financial Results
November 02, 2022
From
Veracyte, Inc.
Via
Business Wire
Earnings Scheduled For November 2, 2022
November 02, 2022
Companies Reporting Before The Bell • Nomura Holdings (NYSE:NMR) is likely to report earnings for its second quarter.
Via
Benzinga
Veracyte Announces Three Abstracts to Be Presented at SITC 2022 Annual Meeting
November 01, 2022
From
Veracyte, Inc.
Via
Business Wire
Veracyte to Participate in the Credit Suisse 31st Annual Healthcare Conference
October 27, 2022
From
Veracyte, Inc.
Via
Business Wire
New Data Suggest Decipher GRID-Derived Genomic Signature Can Help Identify Men with Prostate Cancer Who Should Receive High-Dose Radiotherapy
October 25, 2022
From
Veracyte, Inc.
Via
Business Wire
Veracyte Data Presented at ATA Annual Meeting Provide New Insights into Molecular Underpinnings of Thyroid Cancer
October 24, 2022
From
Veracyte, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Wednesday's After-Market Session
October 19, 2022
Gainers ASLAN Pharma (NASDAQ:ASLN) stock moved upwards by 13.7% to $0.54 during Wednesday's after-market session. The market value of their outstanding shares is at $37.6 million.
Via
Benzinga
New Data Presented at CHEST 2022 Reinforce Clinical Value of Veracyte’s Genomic Tests in Interstitial Lung Disease and Lung Cancer
October 18, 2022
From
Veracyte, Inc.
Via
Business Wire
Veracyte to Release Third Quarter 2022 Financial Results on November 2, 2022
October 13, 2022
From
Veracyte, Inc.
Via
Business Wire
New Data Published in JNCI Demonstrate Veracyte’s Decipher Prostate Genomic Classifier May Improve Identification of Aggressive Prostate Cancer in African American Men
September 22, 2022
From
Veracyte, Inc.
Via
Business Wire
Veracyte Names John Leite, Ph.D., as General Manager of Pulmonology & Market Access
September 13, 2022
From
Veracyte, Inc.
Via
Business Wire
New Data Presented at ESMO 2022 Show Veracyte’s Decipher Prostate Genomic Classifier May Help Inform Personalized Treatment Decisions in Men with Advanced Prostate Cancer
September 11, 2022
From
Veracyte, Inc.
Via
Business Wire
New Data Suggest Veracyte’s Envisia Genomic Classifier Can Help Predict Disease Progression in Interstitial Lung Disease Patients Treated with Combination Immunosuppressive Therapy
September 07, 2022
From
Veracyte, Inc.
Via
Business Wire
Veracyte to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
September 01, 2022
From
Veracyte, Inc.
Via
Business Wire
Veracyte Announces Seven Abstracts to Be Presented at ESMO Congress 2022
August 31, 2022
From
Veracyte, Inc.
Via
Business Wire
New Data in Nature Medicine Suggest Pre-Treatment Tumor Microenvironment Can Impact Response for CAR T-Cell Therapy in Patients with Large B-Cell Lymphoma
August 29, 2022
From
Veracyte, Inc.
Via
Business Wire
Whither Small Caps After Fed’s Tough Talk?
August 29, 2022
For now its better not to “Fight the Fed” because they are fighting the with the market. Now that everyone is scared of the Fed's rhetoric it would be better to wait a week or so as more data and...
Via
Talk Markets
Veracyte Appoints Eliav Barr, M.D., to Its Board of Directors
August 11, 2022
From
Veracyte, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.